trending Market Intelligence /marketintelligence/en/news-insights/trending/if3f46ffnuRTcoRMqca7YQ2 content esgSubNav
In This List

Veloxis Pharmaceuticals appoints chief commercial officer

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Veloxis Pharmaceuticals appoints chief commercial officer

Veloxis Pharmaceuticals A/S promoted Mark Hensley to the role of chief commercial officer.

Hensley has been serving as the company's vice president of sales since May 2017. He also held different senior leadership roles in Chiesi USA Inc. and Cornerstone Therapeutics Inc. before joining Veloxis.

Copenhagen-based Veloxis Pharmaceuticals is a specialty pharmaceutical company that develops and commercializes products used in transplant procedures and adjacent therapies.